Aytu BioPharma, Inc. — Form 10-Q Summary
Reporting period: Fiscal second quarter and six months ended December 31, 2023. All financial amounts below are in U.S. dollars; millions are shown as $m unless otherwise noted.
Business context
Aytu commercializes prescription pharmaceuticals through its Rx segment and consumer healthcare products through its Consumer Health segment. Its Rx portfolio includes ADHD products Adzenys XR-ODT and Cotempla XR-ODT, plus pediatric products. The company is winding down Consumer Health during fiscal 2024 and moving ADHD production to a third-party manufacturer. Active development of clinical programs, including AR101, has been suspended.
Key financial results
| Metric | Three months ended Dec. 31, 2023 | Three months ended Dec. 31, 2022 | Six months ended Dec. 31, 2023 | Six months ended Dec. 31, 2022 |
|---|---|---|---|---|
| Net revenue | $22.9m | $26.3m | $45.0m | $53.9m |
| Gross profit / margin | $16.2m / 71% | $17.3m / 66% | $31.0m / 69% | $35.3m / 65% |
| Operating income (loss) | $2.4m | $(6.9)m | $0.9m | $(8.7)m |
| Net loss | $(0.2)m | $(6.7)m | $(8.3)m | $(7.4)m |
Quarterly revenue declined 13%; six-month revenue declined 17%. Rx revenue was $18.7m for the quarter, up from $18.0m, while Consumer Health revenue fell to $4.2m from $8.3m. Within Rx, quarterly ADHD revenue rose to $16.6m from $11.1m, partly offset by lower Pediatric Portfolio revenue. Gross margin improved as the lower-margin Consumer Health business contracted and the company reported cost and production efficiencies.
For the six months, operating cash use was $0.3m, compared with $11.6m in the prior-year period. Investing activities used $0.3m and financing activities used $2.9m. Cash and cash equivalents were $19.5m at December 31, down $3.5m from June 30. Accounts receivable was $29.4m; inventory was $13.0m. Current assets were $71.4m and current liabilities were $64.2m.
At December 31, the company reported $15.0m of Avenue Capital term debt, due January 26, 2025, and $1.0m outstanding on its revolving credit line. The Avenue loan carries a final payment fee and an effective interest rate reported as 19.6%. Fixed payment arrangements were $9.0m, including a $6.0m remaining liability related to the terminated Tuzistra agreement. Stockholders’ equity was $32.9m.
Material changes, outlook and risks
- Management reported substantial doubt about the company’s ability to continue as a going concern, citing the Avenue Note and uncertainty about funding operations. Management expects to refinance the $15m note and also plans to improve operating cash flow, wind down Consumer Health, and potentially raise capital or monetize assets. It gave no assurance these measures will succeed.
- Management expects the Consumer Health wind-down and suspended development programs to reduce spending; suspension of development programs was expected to save more than $20m in projected study costs over three fiscal years. No specific revenue or earnings guidance was provided.
- Inflation, supplier costs, and supply-chain disruptions may continue through fiscal 2024. The company reported no recent ADHD product stock-outs and adequate pediatric product supply, but warned that disruptions and higher costs could affect results.
- Noncash fair-value losses on derivative warrant liabilities were $0.6m for the quarter and $6.5m for the six months; the liability rose to $12.9m from $6.4m at June 30. These valuation changes contributed to the difference between operating results and net results.
- The company recorded $0.8m of income tax expense in the quarter and six-month period. It cited ownership-change limitations under Section 382 and existing valuation allowances. A $3.8m Employee Retention Credit received in the first quarter was recorded as a liability pending regulatory audit or further IRS clarification; a related $0.4m vendor fee was expensed.
- Disclosure controls were deemed ineffective because of material weaknesses in accounting for complex warrants and inventory valuation. Management and the Audit Committee described remediation efforts; the weaknesses will not be considered remediated until controls operate effectively and are tested.
- Legal matters include a Stein employment lawsuit, whose financial impact the company said it could not predict; the Sabby and Walleye warrant litigation was settled in October 2023. A separate stockholder derivative litigation settlement remains subject to court approval.
Important facts for investors to verify
- Whether Aytu refinances or otherwise repays the $15m Avenue Note before its January 2025 maturity, and the resulting terms and liquidity impact.
- Cash generation, accounts-receivable collections, and operating performance as Consumer Health is wound down and ADHD manufacturing transitions to a third party.
- Whether the ERC proceeds are ultimately recognized as income or subject to repayment after IRS review.
- Progress in remediating the warrant-accounting and inventory-valuation material weaknesses.
- Potential dilution and warrant-related volatility: 6.48m warrants were outstanding at December 31, compared with 5.57m common shares outstanding.
- Developments in the Stein and derivative lawsuits, and any costs or obligations arising from the settlements and product agreements.